Company profile for NeuExcell therapeutics

NEW Drugs in Dev: 1
PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

NeuExcell is an early stage gene therapy company focusing on neurodegenerative diseases. We have developed a disruptive neural repair technology that utilizes in vivo astrocyte-to-neuron conversion. Our vision is to improve the quality of life of millions of patients worldwide who are suffering from neurodegenerative conditions by using the power of gene therapy to restore damaged neural tissue.The newly generated neurons in...
NeuExcell is an early stage gene therapy company focusing on neurodegenerative diseases. We have developed a disruptive neural repair technology that utilizes in vivo astrocyte-to-neuron conversion. Our vision is to improve the quality of life of millions of patients worldwide who are suffering from neurodegenerative conditions by using the power of gene therapy to restore damaged neural tissue.The newly generated neurons integrate into existing brain circuits, leading to functional recovery. This technology has a broad scope of applications to treat neurodegenerative diseases and neural injuries.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
200 Innovation Blvd., Suite 258B State College, PA 16803
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/12/18/3207988/0/en/NeuExcell-Therapeutics-Reports-Encouraging-Clinical-Results-with-World-s-First-In-Situ-Conversion-Therapy-for-Malignant-Glioma.html

GLOBENEWSWIRE
18 Dec 2025

https://www.prnewswire.com/news-releases/neuexcells-aav-gene-therapy-for-malignant-glioma-granted-orphan-drug-designation-by-fda-302017315.html

PR NEWSWIRE
18 Dec 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty